Americans live with chronic ocular surface pain; no therapy is approved specifically to treat it1,2. Most of these patients sit inside the dry-eye segment, but existing therapies treat signs and symptoms of DED, not ocular pain1,2. This large, identifiable, and structurally undertreated market is open to the first pain-labeled category leader 1